DrugId:  1
1. Name:  Latiglutenase
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in gastrointestinal diseases and disorders (miscellaneous) and autoimmune diseases such as celiac disease.
DrugId:  2
1. Name:  Hydroxocobalamin
2. Groups:  Approved
3. Description:  Hydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is an injectable form of vitamin B 12 that has been used therapeutically to treat vitamin B 12 deficiency. Other uses include cyanide poisoning, Leber's optic atrophy, and toxic amblyopia.
4. Indication:  For treatment of pernicious anemia and the prevention and treatment of vitamin B12 deficiency arising from alcoholism, malabsorption, tapeworm infestation, celiac, hyperthyroidism, hepatic-biliary tract disease, persistent diarrhea, ileal resection, pancreatic cancer, renal disease, prolonged stress, vegan diets, macrobiotic diets or other restrictive diets. Also for the treatment of known or suspected cyanide poisoning.
DrugId:  3
1. Name:  Kappadione
2. Groups:  Approved
3. Description:  Kappadione is a Vitamin K derivative (chemically, it is menadiol sodium diphosphate), previously approved by FDA prior to 1982 and marketed by Lilly Marketing for this drug has been discontinued and is not available in North America [3]. It has been found to have carcinogenic potential in mammalian cells as well as cytotoxic properties [4]. Studies involving the active metabolite of this formulation, menadione, showed oocyte toxicity in a study of mice [4].
4. Indication:  Anticoagulant-induced prothrombin deficiency caused by coumadin or indanedione derivatives,prophylaxis and therapy of hemorrhagic disease of the newborn, hypoprothrombinemia due to antibacterial therapy,hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K (for example, obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis, other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism) [5, 6].
DrugId:  4
1. Name:  Prednisolone
2. Groups:  Approved, Vet approved
3. Description:  A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]
4. Indication:  For the treatment of primary or secondary adrenocortical insufficiency, such as congenital adrenal hyperplasia, thyroiditis. Also used to treat psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, bursitis, acute gouty arthritis and epicondylitis. Also indicated for treatment of systemic lupus erythematosus, pemphigus and acute rhematic carditis. Can be used in the treatment of leukemias, lymphomas, thrombocytopenia purpura and autoimmune hemolytic anemia. Can be used to treat celiac disease, insulin resistance, ulcerative colitis and liver disorders.
DrugId:  5
1. Name:  ADC4022
2. Groups:  Investigational
3. Description:  ADC4022 is an investigational medicine for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and severe asthma.
4. Indication:  Investigated for use/treatment in asthma and chronic obstructive pulmonary disease (COPD).
DrugId:  6
1. Name:  DLO6001
2. Groups:  Investigational
3. Description:  DL6001 is developed by DanioLabs using proprietary zebrafish technology to treat Parkinsonâ€™s disease symptoms including sialorrhoea and hyperhidrosis.
4. Indication:  Investigated for use/treatment in parkinson's disease.
DrugId:  7
1. Name:  DLO6002
2. Groups:  Investigational
3. Description:  DLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.
4. Indication:  Investigated for use/treatment in parkinson's disease.
DrugId:  8
1. Name:  Mito-4509
2. Groups:  Investigational
3. Description:  Mito-4509 is a non-feminizing estrogen analog that could affect mitochondrial metabolic pathways. It is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic Disorders. 
4. Indication:  Investigated for use/treatment in alzheimer's disease, neurologic disorders, parkinson's disease, and retinal disorders (unspecified).
DrugId:  9
1. Name:  Lexaptepid Pegol
2. Groups:  Investigational
3. Description:  Lexaptepid Pegol has been used in trials studying the treatment of Anemia, Inflammation, Chronic Diseases, End Stage Renal Disease, and Anemia of Chronic Disease.
4. Indication:  Not Available
DrugId:  10
1. Name:  FP0011
2. Groups:  Investigational
3. Description:  FP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease). It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties.
4. Indication:  Investigated for use/treatment in amyotrophic lateral sclerosis (ALS) and parkinson's disease.
DrugId:  11
1. Name:  KC706
2. Groups:  Investigational
3. Description:  KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. KC706 holds potential to treat inflammatory conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and cardiovascular disease.
4. Indication:  Investigated for use/treatment in cardiovascular disorders, inflammatory bowel disease, inflammatory disorders (unspecified), psoriasis and psoriatic disorders, and rheumatoid arthritis.
DrugId:  12
1. Name:  CAD106
2. Groups:  Investigational
3. Description:  CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients. 
4. Indication:  Investigated for use/treatment in alzheimer's disease.
DrugId:  13
1. Name:  Opebacan
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in crohn's disease, congenital anomaly (unspecified), cardiovascular disorders, pediatric indications, and burns and burn infections.
DrugId:  14
1. Name:  ALKS 27
2. Groups:  Investigational
3. Description:  ALKS 27 is an inhaled formulation of trospium chloride for the treatment of chronic obstructive pulmonary disease (COPD). Study showed that ALKS 27 was well-tolerated over a wide dose range, with no dose-limited effects observed.
4. Indication:  Investigated for use/treatment in chronic obstructive pulmonary disease (COPD).
DrugId:  15
1. Name:  AVI-4020
2. Groups:  Investigational
3. Description:  AVI-4020 is a neugene antisense drug candidate for the treatment of patients with acute West Nile virus disease who have serious neurological impairment (WNV neuroinvasive disease).
4. Indication:  Investigated for use/treatment in infectious and parasitic disease (unspecified) and viral infection.
DrugId:  16
1. Name:  AP1903
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in bone marrow transplant and graft versus host disease.
DrugId:  17
1. Name:  Ilodecakin
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in inflammatory disorders (unspecified), crohn's disease, and rheumatoid arthritis.
DrugId:  18
1. Name:  P54
2. Groups:  Investigational
3. Description:  P54 reduces the inflammation associated with cancer/tumors, Crohn's disease, inflammatory bowel disease, osteoarthritis, and ulcerative colitis. It inhibits the induction of the enzyme NFkB, thereby inhibiting downstream inflammatory genes such as COX II and iNOS.
4. Indication:  Investigated for use/treatment in cancer/tumors (unspecified), crohn's disease, inflammatory bowel disease, osteoarthritis, and ulcerative colitis.
DrugId:  19
1. Name:  PBT-1033
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in alzheimer's disease.
DrugId:  20
1. Name:  Crenezumab
2. Groups:  Investigational
3. Description:  Crenezumab has been used in trials studying the treatment of Alzheimer's Disease.
4. Indication:  Not Available
DrugId:  21
1. Name:  Inclacumab
2. Groups:  Investigational
3. Description:  Inclacumab has been used in trials studying the treatment and prevention of Myocardial Infarction, Peripheral Arterial Disease (PAD), and Coronary Heart Disease, Graft Occlusion, Vascular.
4. Indication:  Not Available
DrugId:  22
1. Name:  Condoliase
2. Groups:  Investigational
3. Description:  Condoliase has been used in trials studying the treatment of Lumbar Disc Disease, Lumbar Vertebra Hernia, and Intervertebral Disc Disease.
4. Indication:  Not Available
DrugId:  23
1. Name:  Solanezumab
2. Groups:  Investigational
3. Description:  Solanezumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial.
4. Indication:  Not Available
DrugId:  24
1. Name:  Edifoligide
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in cardiac surgery, peripheral vascular disease, and kidney disease.
DrugId:  25
1. Name:  Gantenerumab
2. Groups:  Investigational
3. Description:  Gantenerumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial.
4. Indication:  Not Available
